Iron and carcinogenesis in laboratory animals and humans: A mechanistic consideration and a review of literature

International Journal of Clinical Oncology

Volumn 3, Issue 4, 1998, Pages 191-203

  Okada, Shigeru ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Carcinogenesis; Free radical; Hemochromatosis; Iron; Iron withholding; Lipid peroxidation; Oxygen

Indexed keywords

ALPHA TOCOPHEROL; CHELATING AGENT; DEOXYGUANOSINE DERIVATIVE; FREE RADICAL; IRON;

APOPTOSIS; CHEMICAL CARCINOGENESIS; DNA DAMAGE; ELECTRON TRANSPORT; HEMOCHROMATOSIS; HUMAN; IRON KINETICS; IRON METABOLISM; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW; SEX DIFFERENCE; TISSUE INJURY;

EID: 0031713734     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02489833     Document Type: Review

References (126)

1. Perls M. Nachweis von eisenoxyd. In: Gewissen pigmenten. Virchows Archiv 1867;39:42-48.
2. Loehlein W. Drei Falle von primarem leberkarcinom. Beitrage zur pathol anat und zur allg pathol 1907;XVIII:531-558.
3. Mills ES. Hemochromatosis with special reference to its frequency and to its occurrence in women. Arch Int Med 1924;34:292-300.
4. Stewart MJ. The cirrhosis of haemochromatosis and carcinoma of liver in cirrhosis and haemochromatosis. Brit Med J 1922;2:1065-1067.
5. Althausen TL, Kerr WJ. Hemochromatosis. A report of three cases with results of insulin therapy in one case. Endocrinology 1927;II:377-422.
6. Dreyfus JR. Lungencarcinom bei geschwistern nach inhalation von eisenoxydhaltigem Staub in der Jugend. Zeit Klin Med 1936;130:256-260.
7. Warren S, Drake Jr WL. Primary carcinoma of the liver in hemochromatosis. Am J Pathol 1951;27:573-609.
8. Richmond HG. Induction of sarcoma in the rat by iron-dextran complex. Brit Med J 1959;i:947-949.
9. Haddow A, Horning ES. On the carcinogenicity of an iron-dextran complex. J Natl Cancer Inst 1960;24:109-147.
10. Robinson CEG, Bell DN, Sturdy JH. Possible association of malignant neoplasm with iron-dextran injection. A case report. Brit Med J 1960;11:648-650.
11. Greenberg G. Sarcoma after intramuscular iron injection. Brit Med J 1976;1:1508-1509.
12. Weinbren K, Salm R, Greenberg G. Intramuscular injections of iron compounds and oncogenesis in man. Brit Med J 1978;1:683-685.
13. McDonald RA. Hemochromatosis and Hemosiderosis. Springfield: Charles C. Thomas, 1964.
14. Ammann RW, Muller E, Bansky J, Schuler G, Hacki WH. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand J Gastroenterol 1980;15:733-736.
15. Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM, Halliday JW, Bassett ML, Powell LW. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81-84.
16. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. New Engl J Med 1985;313:1256-1262.
17. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Quart J Med 1976;45:611-623.
18. Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron Metabolism in Man. Oxford: Blackwell Scientific Pub.,1979.
19. Powell LW, Halliday JW. Idiopathic haemochromatosis. In: Iron in biochemistry and medicine, II. London: Academic Press, 1980:461-498.
20. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
21. Gangaidzo IT, Gordeuk VR. Hepatocellular carcinoma and African iron overload. Gut 1995;37:727-730.
22. Gordeuk VR, Mclaren CE, Macphail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996;87:3470-3476.
23. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Physiol Rev 1984;64:65-102.
24. Weinberg ED. Iron, infection, and neoplasia. Clin Physiol Biochem 1986;4:50-60.
25. Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990;75:1903-1919.
26. Weinberg ED. Roles of iron in neoplasia - promotion, prevention, and therapy. Biol Trace Element Res 1992;34:123-140.
27. Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasia. Life Sci 1992;50:1289-1297.
28. Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 1997;75:1164-1180.
29. Selig RA, White L, Gramacho C, SterlingLevis K, Fraser IW, Naidoo D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res 1998;58:473-478.
30. Cabantchik ZI, Glickstein H, Golenser J, Loyevsky M, Tsafack A. Iron chelators: mode of action as antimalarials. Acta Haematol 1996;95:70-77.
31. Awai M, Narasaki M, Yamanoi Y, Seno S. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. Am J Pathol 1979;95:663-674.
32. Okada S, Midorikawa, O. Induction of the rat renal adenocarcinoma by Fe-nitrilotriacetate (Fe-NTA) (in Japanese). Jpn Arch Intern Med (Naika Hokan) 1982;29:485-491.
33. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest 1983;71:429-439.
34. Pryor WA (ed). Free Radicals in Biology. New York: Academic Press, 1976 through 1984: vol. 1 through 6.
35. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969;244:6049-6055.
36. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 2nd ed. Oxford: Oxford University Press, 1989:126-130.
37. Davies KJA (ed). Oxidative Damage and Repair. Oxford: Pergamon Press, 1991.
38. Moslen MT, Smith CV (eds). Free Radical Mechanisms of Tissue Injury. Boca Raton: CRC Press, 1992.
39. Rice-Evans CA, Burdon RH (eds). Free radical damage and its control. In: New comprehensive biochemistry. Amsterdam: Elsevier, 1994:28.
40. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disese: an overview. In: Oxygen radicals in biological systems. Methods in enzymology. San Diego: Academic Press, 1990:186:1-85.
41. Lauffer RB. Iron and Human Disease. Boca Raton: CRC Press, 1992.
42. Weinberg ED. The role of iron in cancer. Eur J Cancer Prevent 1996;5:19-36.
43. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-566.
44. Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int 1996;46:311-332.
45. Spiro TG, Saltman P. Inorganic chemistry. In: Iron in biochemistry and medicine. New York: Academic Press, 1974:1-28.
46. Neilands JB, Konopka K, Schwyn B, Coy M, Francis RT, Paw BH, Bagg A. Comparative biochemistry of microbial iron. In: Iron transport in microbes, plants and animals. Weinheim: VCH Verlagsgesellshaft, 1987:3-33.
47. Winkelmann G, van der Helm D, Neilands JB (eds). Iron Transport in Microbes, Plant and Animals. Weinheim: VCH Verlagsgesellshaft, 1987.
48. Spiro T. Chemistry and biochemistry of iron. In: Proteins of iron metabolism. New York: Grime & Stratton, 1977:xxii-xxxii.
49. Hamazaki S, Okada S, Li J-L,Toyokuni S, Midorikawa O. Oxygen reduction and lipid peroxidation by iron chelates with special reference to ferric nitrilotriacetate. Arch Biochem Biophys 1989;272:10-17.
50. Aust SD, Morehouse LA, Thomas CE. Role of metals on oxygen radical reactions. J Free Rad Biol Med 1985;1:3-25.
51. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. J Am Med Assoc 1997;277:973-976.
52. Brock JH, Halliday JW, Pippard MJ, Powell LP (eds). Iron Metabolism in Health and Disease. London: WB Saunders, 1994.
53. Beard JL, Dawson H, Pinero DJ. Iron metabolism: a comprehensive review. Nutr Rev 1996;54:295-317.
54. Worwood M. The laboratory assessment of iron status - an update. Clin Chim Acta 1997;259:3-23.
55. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. In: Current topics in cellular regulation. San Diego: Academic Press, 1997;35:1-19.
56. Benito P, Miller D. Iron absorption and bioavailability: an updated review. Nutr Res 1998;18:581-603.
57. Conrad ME, Crosby WH. Intestinal mucosal mechanisms controlling iron absorption. Blood 1963;22:406-415.
58. Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990;75:1903-1919.
59. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
60. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-1477.
61. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482-488.
62. Dennery PA, Spitz DR,Yang G,Tatarov A, Lee CS, Shegog ML, Poss KD. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 1998;101:1001-1011.
63. MacKinnon AE, Bancewicz J. Sarcoma after injection of intramuscular iron. Brit Med J 1973;2:277-279.
64. Robertson AG, Dick WC. Intramuscular iron and local oncogenesis. Brit Med J 1977:946.
65. Kennaway NM, Kennaway EL. A study of the incidence of cancer of the lung and larynx. J Hyg 1936;36:236-267.
66. Turner HM, Grace HG. An investigation into cancer mortality among males in certain Sheffield trades. J Hyg 1938;38:90-103.
67. Boyd JT, Doll R, Faulds JS, Leiper J. Cancer of the lung in iron ore (haematite) miners. Brit J Indust Med 1970;27:97-105.
68. Anthoine D, Braun P, Cervoni P, Schwartz P, Lamy P. Le cancer bronchique des mineurs de fer de Lorraine Peut-Iletre considere comme une maladie professionnelle? A propos de 270 nouveaux cas observes de 1964 a 19781. Rev Fr Mal Respir 1979;7:63-65.
69. Edling C. Lung cancer and smoking in a group of iron ore miners. Amer J Indust Med 1982;3:191-199.
70. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. New Engl J Med 1988;319:1047-1052.
71. Freudenheim L, Graham S, Marshall JR, Haughey BP, Wilkinson G. A case-control study of diet and rectal cancer in western New York. Am J Epidemiol 1990;131:612-624.
72. Sherson D, Svane O, Lynge E. Cancer incidence among foundry workers in Denmark. Arch Environ Health 1991;46:75-81.
73. Akiba S, Neriishi K, Blot WJ, Kabuto M, Stevens RG, Kato H, Land CE. Serum ferritin and stomach cancer risk among a Japanese population. Cancer 1991;67:1707-1712.
74. Friedman GD, van den Eeden SK. Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol 1993;22:30-37.
75. Icso J, Szollosova M, Sorahan T. Lung cancer among iron ore miners in east Slovakia: a case-control study. Occup Environ Medicine 1994;51:642-643.
76. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-369.
77. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-382.
78. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, Fraumeni JFJ. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-162.
79. Herrinton LJ, Friedman GD, Baer D, Selby JV. Transferrin saturation and risk of cancer. Am J Epidemiol 1995;142:692-698.
80. Van Asperen IA, Feskens EJM, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995;24:665-670.
81. Turlin B, Juguet F, Moirand R, Lequilleuc D, Loreal O, Campion JP, Launois B, Ramee MP, Brissot P, Deugnier Y. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995;22:446-450.
82. Mandel JS, Mclaughlin JK, Schlehofer B, Mellemgaard A, Helmert U, Lindblad P, Mccredie M, Adami HO. International renal-cell cancer study. Part IV. Occupation. Int J Cancer 1995;61:601-605.
83. Van der Gulden JWJ, Kolk JJ,Verbeek ALM. Work environment and prostate cancer risk. Prostate 1995;27:250-257.
84. Campbell JA. Lung tumours in mice and man. Brit Med J 1943;I:179-183.
85. Lundin PM. The carcinogenic action of complex iron preparations. Brit J Cancer 1961;15:838-847.
86. Haddow A, Roe FJC, Mitchley BCV. Induction of sarcomata in rabbits by intramuscular injection of iron-dextran ("Imferon"). Brit Med J 1964;1593-1594.
87. Roe FJC, Haddow A, Dukes CE, Mitchley BCV. Iron-dextran carcinogenesis in rats: effect of distributing injected material between one, two, four, or six sites. Brit J Cancer 1964;18:801-808.
88. Magnusson G, Flodh H, Malmfors T. Oncological study in rats of ferastral, an iron-poly-(sorbitol-gluconic acid) complex, after intramuscular administration. Scand J Haematol 1977;32:87-98.
89. Li J-L, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 1987;47:1867-1869.
90. Okada S Hamazaki, S, Toyokuni, S, Midorikawa, O. Induction of mesothelioma by intraperitoneal injection of ferric saccharate in male Wistar rats. Brit J Cancer 1989;60:708-700.
91. Liu M, Okada S. Induction of free radicals and tumors in the kidneys of Wistar rats by ferric ethylenediamine-N, N'-diacetate. Carcinogenesis 1994;15:2817-2821.
92. Halliwell B, Aruoma OI. DNA and Free Radicals. West Sussex: Ellis Horwood, 1993.
93. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997;387:147-163.
94. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32A:30-38.
95. 5. Toyokuni S, Luo X-P, Tanaka T, Uchida K, Hiai H, Lehotay DC. Induction of a wide range of C2-12 aldehydes and C7-12 acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Radic Biol Med 1997;22:1019-1027.
96. Uchida K. HNE modified proteins: origin of oxidative stress response. 1996;15:1394-1401.
97. Uchida K. Characterization of oxidative stress with protein modifiers as probes (in Japanese). Nippon Nogeikagaku Kaishi (Proc Jpn Agriculture Chem) 1996;70:1087-1093.
98. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1993;57:S779-S786.
99. Esterbauer H. Estimation of peroxidative damage - a critical review. Pathol Biol 1996;44:25-28.
100. Hamazaki S, Okada S,Toyokuni S, Midorikawa O. Thiobarbituric acid-reactive substance formation of rat kidney brush border membrane vesicles induced by ferric nitrilotriacetate. Arch Biochem Biophys 1989;274:348-354.
101. Spear N, Aust SD. Thiol-mediated NTA-Fe(III) reduction and lipid peroxidation. Arch Biochem Biophys 1994;312:198-202.
102. Okada S, Minamiyama Y, Hamazaki S, Toyokuni S, Sotomatsu A. Glutathione cycle dependency of ferric nitriolotriacetate-induced lipid peroxidation in mouse proximal renal tubules. Arch Biochem Biophys 1993;301:138-142.
103. Okada S, Hamazaki S, Ebina Y, Li J-L, Midorikawa O. Nephrotoxicity and its prevention by vitamin E in ferric nitrilotriacetate-promoted lipid peroxidation. Biochim Biophys Acta 1987;922:28-33.
104. Toyokuni S, Okada S, Hamazaki S, Minamiyama Y, Yamada Y, Liang P, Fukunaga Y, Midorikawa O. Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res 1990;50:5574-5580.
105. Okada S, Fukunaga Y, Hamazaki S, Yamada Y, Toyokuni S. Sex differences in the localization and severity of ferric nitrilotriacetate-induced lipid peroxidation in the mouse kidney. Acta Pathol Jpn 1991;41:221-226.
106. Deguchi J, Miyamoto M, Okada S. Sex hormone dependent renal cell carcinogenesis induced by ferric nitrilotriacetate in Wistar rats. Jpn J Cancer Res 1995;86:1068-1071.
107. Ebina Y, Okada S, Hamazaki S, Ogino F, Li J-L, Midorikawa O. Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitrilotriacetate complexes in rats. J Natl Cancer Inst 1986;76:107-113.
108. Toyokuni S, Okada S, Hamazaki S, Fujioka M, Li J-L, Midorikawa O. Cirrhosis of the liver induced by cupric nitrilotriacetate in Wistar rats, an experimental model of copper toxicosis. Am J Pathol 1989;134:1263-1274.
109. Toyokuni S, Tanaka T, Nishiyama Y, Okamoto K, Nakashima Y, Hamazaki S, Okada S, Hiai H. Induction of renal cell carcinoma in male Wistar rats treated with cupric nitrilotriacetate. Lab Invest 1996;75:239-248.
110. Zhang DX, Okada S, Yu YY, Zheng P, Yamaguchi R, Kasai H. Vitamin E inhibits apoptosis, DNA modification, and cancer incidence induced by iron-mediated peroxidation in Wistar rat kidney. Cancer Research 1997;57:2410-2414.
111. Umemura T, Sai K, Takagi A, Hasegawa R, Kurokawa Y. Formation of 8-hydroxydeoxyguanosine (8-OH-dG) in rat kidney DNA after intraperitoneal administration of ferric nitrilotriacetate (Fe-NTA).Carcinogenesis 1990;11:345-347.
112. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated wit a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994;57:123-128.
113. Yamaguchi R, Hirano T, Asami S, Chung MH, Sugita A, Kasai H. Increased 8-hydroxyguanine levels in DNA and its repair activity in rat kidney after administration of a renal carcinogen, ferric nitrilotriacetate. Carcinogenesis 1996;17:2419-2422.
114. Stoian I, Oros A, Moldoveanu E. Apoptosis and free radicals. Biochem Mol Med 1996;59:93-97.
115. Kawabata T, Ma YX, Yamadori I, Okada S. Iron-induced apoptosis in mouse renal proximal tubules after an injection of a renal carcinogen, iron-nitrilotriacetate. Carcinogenesis 1997;18:1389-1394.
116. Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat Res 1991;250:3-16.
117. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993;90:7915-7922.
118. Biemond P, van Eijk HG, Swaak AJG, Koster JF. Iron mobilization from ferritin by Superoxide derived from stimulated polymorphonuclear leukocytes: possible mechanism in inflammation diseases. J Clin Invest 1984;73:1576-1579.
119. Biemond P, Swaak AJG, Beindorff CM, Koster JF. Superoxide-dependent and -independent mechanisms of iron mobilization from ferritin by xanthine oxidase. Implications for oxygen-free-radical-induced tissue destruction during ischaemia and inflammation. Biochem J 1986;239:169-173.
120. Green R, Esparza I, Schreiber R. Iron inhibits the non-specific tumoricidal activity of macrophages: a possible contributory mechanism for neoplasia in hemochromatosis. Ann NY Acad Sci 1988;526:301-309.
121. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
122. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels and an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 1995;22:268-271.
123. Shedlofsky SI. Role of iron in the natural history and clinical course of hepatitis C disease. Hepatogastroenterology 1998;45:349-355.
124. Kato J, Kobune M, Kohgo Y, Sugawara N, Hisai H, Nakamura T, Sakamaki S, Sawada N, Niitsu Y. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in LEG rats. J Clin Invest 1996;98:923-929.
125. Carmine TC, Evans P, Bruchelt G, Evans R, Handgretinger R, Niethammer D, Halliwell B. Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. Cancer Lett 1995;94:219-226.
126. Harrison P, Neilson JR, Marwah SS, Madden L, Bareford D, Milligan DW. Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol 1996;49:853-856.